论文部分内容阅读
目的 评价降纤酶治疗急性脑梗死的临床疗效及与中药川芎嗪的比较。 方法 采用前瞻性、随机、双盲对照的方法。选择 2 4 h内的患者。降纤酶第 1天 1 0 u,第 3、 5天各 5 u静滴。 结果 降纤酶组急性期治愈率高于对照组 ,有显著差异 ;1 2周治愈率接近。神经功能缺损评分及 Barthel指数略好于对照组 ,但无显著差异。降纤酶组治疗后纤维蛋白原明显降低 ,与治疗前及对照组比较 ,有非常显著差异。结论 降纤酶有显著降低血纤维蛋白原作用 ,对 2 4 h内急性脑梗死疗效较川芎嗪略好。无明显毒副作用。
Objective To evaluate the clinical efficacy of defibrase in the treatment of acute cerebral infarction and compare with tetramethylpyrazine. Methods A prospective, randomized, double-blind, controlled trial was used. Select patients within 24 hours. Defibrase on the first day 1 0 u, 3, 5 days of 5 u intravenous infusion. Results defibrase in the acute phase of the cure rate was higher than the control group, a significant difference; 12 weeks cure rate close. Neurological deficit scores and Barthel index slightly better than the control group, but no significant difference. Fibrinogen after defibrase treatment significantly reduced compared with before treatment and control group, there is a very significant difference. Conclusion Defibrase has a significant effect of reducing fibrinogen, and its effect is better than tetramethylpyrazine in acute cerebral infarction within 24 hours. No obvious side effects.